Drug Profile
Foliglurax - Lundbeck
Alternative Names: Foliglurax; Foliglurax-Prexton-Therapeutics; PXT-2331; PXT002331Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Domain Therapeutics
- Developer Lundbeck A/S; Prexton Therapeutics
- Class Antiparkinsonians; Morpholines; Pyridines; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 27 Mar 2020 H. Lundbeck A/S discontinues a phase I trial in healthy volunteers in France
- 27 Mar 2020 Discontinued - Phase-I for Parkinson's disease (Treatment-experienced) in Sweden (PO)
- 27 Mar 2020 Discontinued - Phase-II for Parkinson's disease (Treatment-experienced) in Germany, Austria, France, United Kingdom, Italy and Spain (PO)